Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease

European Journal of Neurology

Volumn 20, Issue 1, 2013, Pages 50-56

  Schapira, A H V ^a   Barone, P ^b   Hauser, R A ^c   Mizuno, Y ^d   Rascol, O ^e   Busse, M ^f   Debieuvre, C ^g   Fraessdorf, M ^f   Poewe, W ^h  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^g BOEHRINGER INGELHEIM   (France)

^h INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Pramipexole; Survey; Three times daily; Unified Parkinson's Disease Rating Scale

Indexed keywords

AMANTADINE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PLACEBO; PRAMIPEXOLE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; EVENING DOSAGE; FEMALE; HEALTH SURVEY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PATIENT PREFERENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERNATIONAL COOPERATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; SELF REPORT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84871669499     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2012.03712.x     Document Type: Article

References (26)

1. Fox SH, Katzenschlager R, Lim SY, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011; 26(Suppl. 3): S2-S41.
2. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 983-995.
3. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease: report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section: part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 2006; 13: 1170-1185.
4. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease: report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES): part II: late (complicated) Parkinson's disease. Eur J Neurol 2006; 13: 1186-1202.
5. Schapira AH. Treatment options in the modern management of Parkinson disease. Arch Neurol 2007; 64: 1083-1088.
6. Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson's disease. Mov Disord 2004; 19: 513-517.
7. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord 2005; 20: 1502-1507.
8. Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord 2009; 24: 826-832.
9. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007; 68: 1108-1115.
10. Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L. Ease-PD Monotherapy Study Investigators. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 2008; 24: 2883-2895.
11. Hersh BP, Earl NL, Hauser RA, Stacy M. Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations. Mov Disord 2010; 25: 927-931.
12. Stocchi F, Giorgi L, Hunter B, Schapira AH. PREPARED: comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. Mov Disord 2011; 26: 1259-1265.
13. Hauser RA, Schapira AHV, Rascol O, et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord 2010; 25: 2542-2549.
14. Poewe W, Rascol O, Barone P, et al. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology 2011; 77: 759-766.
15. Schapira AHV, Barone P, Hauser RA, et al. Extended-release pramipexole in advanced Parkinson's disease: a randomized controlled trial. Neurology 2011; 77: 767-774.
16. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.
17. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009; 15: e22-e33.
18. Kulkarni AS, Balkrishnan R, Anderson RT, Edin HM, Kirsch J, Stacy MA. Medication adherence and associated outcomes in Medicare health maintenance organization-enrolled older adults with Parkinson's disease. Mov Disord 2008; 23: 359-365.
19. Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. Mov Disord 2010; 25: 474-480.
20. Bainbridge JL, Ruscin JM. Challenges of treatment adherence in older patients with Parkinson's disease. Drugs Aging 2009; 26: 145-155.
21. Duarte JW, Bolge SC, Sen SS. An evaluation of patients' preferences for osteoporosis medications and their attributes: the PREFER-International study. Clin Ther 2007; 29: 488-503.
22. Peres MF, Silberstein S, Moreira F, et al. Patients' preference for migraine preventive therapy. Headache 2007; 47: 540-545.
23. Price D, Robertson A, Bullen K, Rand C, Horne R, Staudinger H. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med 2010; 10: 1.
24. Rothenberger A, Becker A, Breuer D, Döpfner M. An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence. Eur Child Adolesc Psychiatry 2011; 20(Suppl. 2): S257-S265.
25. Guirado L, Cantarell C, Franco A, et al. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. Am J Transplant 2011; 11: 1965-1971.
26. Boyle BA, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW. Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression. HIV Clin Trials 2008; 9: 164-176.